In addition, these therapies work by enhancing insulin secretion and slowing gastric emptying
This injectable weight loss drug has been studied at once-weekly doses between 1-12 mg
And does it work better for weight loss than Ozempic and Wegovy
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
45,46 As shown in Figure 2 , GLP-1RAs penetrate the blood-brain barrier and directly activate GLP-1 receptors in the hypothalamus, especially within the ARH nucleus, a key center for appetite regulation
Clinical trial data suggests Retatrutide may provide a higher degree of weight loss
